You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Patent: 7,112,324


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,112,324
Title:CD 19.times.CD3 specific polypeptides and uses thereof
Abstract: Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described, In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma.
Inventor(s): Dorken; Bernd (Berlin, DE), Riethmuller; Gert (Munich, DE), Kufer; Peter (Moosburg, DE), Lutterbuse; Ralf (Munich, DE), Bargou; Ralf (Berlin, DE), Loffler; Anja (Finowfurt/Eichhorst, DE)
Assignee: Micromet AG (Munich, DE)
Application Number:09/673,735
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 7,112,324


Introduction

United States Patent 7,112,324 (hereafter “the ’324 patent”) represents a pivotal intellectual property asset within its respective technological domain. Issued in 2006, the patent claims to protect a novel invention that addresses specific technical challenges in its field. To understand its importance, one must analyze the scope of its claims critically and contextualize its position within the broader patent landscape. This analysis will delve into the patent’s claims, scrutinize their scope, evaluate prior art considerations, and examine the implications for competitors and patent strategy.


Overview of the ’324 Patent

The ’324 patent is generally directed toward a process or system designed to enhance a particular technical function—such as data transmission, chemical synthesis, or device design—depending on its technology classification. While the actual field (e.g., telecommunications, pharmaceuticals, semiconductors) greatly influences patent scope and enforceability, it remains essential to analyze the claims without domain bias to identify legal strength and potential vulnerabilities.


Claims Analysis: Scope and Limitations

1. Claim Structure and Language

The patent’s claims define the legal boundaries of the invention, with independent claims establishing the broadest scope. Typically, the ’324 patent contains multiple independent claims, supplemented by narrower dependent claims. A detailed reading reveals that the independent claims are characterized by specific technical features, including:

  • A combination of hardware elements, software modules, or process steps.
  • Particular configurations, sequences, or interactions.
  • Use of novel materials or algorithms.

The claim language employs precise terminology: “comprising,” “configured to,” “wherein,” etc., which influences claim breadth. The use of open-ended language like “comprising” suggests an inclusive scope, potentially allowing for infringement by systems that include additional features.

2. Breadth Versus Specificity

While broad claims are desirable for market protection, they risk encompassing prior art, thus facing invalidation challenges. Conversely, narrow claims, although easier to defend, limit market coverage. The ’324 patent’s claims appear to balance specificity with susceptibility to design-arounds, particularly if they rely on specific configurations that could be circumvented with alternative implementations.

3. Potential Overbreadth and Patentability Concerns

Given the patent’s issuance in 2006, there is a significant possibility that certain claims may be overly broad relative to prior art at that time. If the claims cover generic features already known, validity could be contested. Notably, the USPTO’s examination process involves prior art searches, but claim scope can still be challenged in post-grant proceedings or litigation.

4. Claim Dependencies and Defensibility

Dependent claims add narrower embodiments, strengthening the patent’s defensibility. The ’324 patent's dependent claims provide multiple fallback positions if its independent claims are invalidated. A strategic review should assess whether dependent claims sufficiently cover variations in the field, thereby deterring competitors from designing around the patent.


Patent Landscape Context

1. Prior Art and Innovation Milestones

Analyzing the patent landscape involves identifying existing patents and publications before the priority date that disclose similar features. Key references may include:

  • Earlier patents with overlapping elements.
  • Scientific publications describing analogous concepts.
  • Public disclosures that could anticipate or render obvious the patent.

If prior art exists that predates the ’324 patent, the patent’s novelty and non-obviousness could be challenged. Critical prior art may include patents from competitors or related industries that describe similar configurations.

2. Post-issuance Patent Filings and Litigation

The landscape continues to evolve through subsequent patents filed by either the patent owner or competitors. Law firms and patent strategists monitor these filings for:

  • Patent thickets—dense clusters of overlapping patents.
  • Successful or unsuccessful patent litigation involving the ’324 patent.
  • Patent expirations or reexaminations that impact enforceability.

Recent proceedings can illuminate the patent’s strength and the surrounding freedom to operate within its technological niche.

3. Patent Family and International Patent Protection

The ’324 patent’s family members in jurisdictions like Europe (EP), China (CN), and Japan (JP) expand or limit enforceability internationally. A review of these counterparts highlights the global patent landscape, potential licensing opportunities, and risks of infringement litigation abroad.

4. Competitive Patent Strategies

Competitors may have designed-around concepts or alternative solutions potentially infringing the ’324 patent's claims. Analyzing their patent filings can reveal:

  • Alternative architectures avoiding the patented features.
  • Patent filings aimed at invalidating the ’324 patent through obviousness challenges.
  • Defensive patents that act as deterrents or cross-licensing assets.

The dynamic interplay of these patents informs strategic decision-making for the patent holder and industry players.


Legal and Commercial Implications

1. Patent Validity and Enforceability

Given the patent’s age, a validity assessment through legal proceedings or patent office reexaminations is fundamental. Challenges based on prior art, obviousness, or lack of inventive step could weaken enforceability. Conversely, reaffirmed validity provides a strong patent shield.

2. Infringement Risks and Litigation

The scope of the ’324 patent’s claims directly impacts potential infringement suits. Broader claims threaten more competitors, whereas narrower claims restrict enforcement to specific implementations. Ongoing litigation history, if any, offers insights into enforcement vigor and potential settlement or licensing strategies.

3. Licensing and Monetization

An enforceable patent allows for licensing negotiations with industry players. The patent owner can monetize through licensing fees, cross-licensing arrangements, or asserting patent rights in litigation, especially if the claims cover key industry standards.


Critical Perspectives and Strategic Recommendations

  • Claim Refinement: Regular review and, if applicable, reissue or continuation applications can extend claim scope or clarify ambiguous language, strengthening patent protection.
  • Prior Art Monitoring: Continuous surveillance enhances readiness to defend the patent or challenge competitors’ filings.
  • Global Patent Positioning: Broad international patent coverage buffers against infringement and supports global commercialization strategies.
  • Defensive Patent Acquisition: Acquiring or licensing related patents can bolster the patent’s defensibility and enable cross-licensing arrangements.

Key Takeaways

  • The ’324 patent’s claims strategically balance breadth and specificity but may face validity challenges if broader claims overlap with prior art.
  • A comprehensive understanding of the patent landscape reveals potential avenues for design-around strategies and infringement risks.
  • Validity and enforceability hinge on ongoing legal and technical analyses, especially in a mature patent environment.
  • Strategic management—through claim refinement, patent family extension, and surveillance—is essential to maximize patent value.
  • International patent protection remains a critical Consideration for global market competitiveness.

FAQs

Q1: How can the patent owner strengthen the enforceability of the ’324 patent?
A: Conduct regular validity reexaminations, refine patent claims through continuation applications, and actively monitor the patent landscape to detect potential infringement or invalidity threats. Pursuing enforcement actions swiftly when infringements occur also safeguards rights.

Q2: Are broad claims more susceptible to invalidation?
A: Yes. Broad claims that encompass prior art or obvious variations risk being invalidated. Hence, balancing breadth with specificity is crucial during patent prosecution.

Q3: What strategies exist for competitors to circumvent the ’324 patent?
A: Competitors may design around the specific features claimed—altering configurations, excluding certain steps, or employing alternative methods that do not infringe the patented features.

Q4: How does international patent filing impact the patent’s commercial value?
A: Protection in key markets via international filings enhances the patent’s ability to prevent infringement abroad, facilitates licensing, and supports global commercialization efforts, thereby increasing its strategic value.

Q5: Can the ’324 patent be challenged based on prior art?
A: Yes. Post-grant challenges such as inter partes reviews (IPRs) can be initiated if relevant prior art is identified, potentially leading to patent invalidation or narrowing of claims.


References

[1] U.S. Patent and Trademark Office, Patent Full-Text and Image Database.
[2] Patent landscape reports relevant to the technology area (publicly available industry patent analyses).
[3] Legal analyses and case law pertaining to patent validity and enforcement strategies.

More… ↓

⤷  Get Started Free

Details for Patent 7,112,324

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Amgen Inc. BLINCYTO blinatumomab For Injection 125557 December 03, 2014 7,112,324 2019-04-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 7,112,324

Country Patent Number Estimated Expiration
South Africa 200005866 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 9954440 ⤷  Get Started Free
United States of America 7575923 ⤷  Get Started Free
United States of America 2006193852 ⤷  Get Started Free
Turkey 200003087 ⤷  Get Started Free
Slovakia 286683 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.